| Atherosclerosis--an inflammatory disease | New England Journal of Medicine | 1999 | 17.2K |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) | Lancet, The | 1998 | 15.3K |
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report | JAMA - Journal of the American Medical Association | 2003 | 13.5K |
| Dabigatran versus warfarin in patients with atrial fibrillation | New England Journal of Medicine | 2009 | 7.9K |
| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Lancet, The | 2004 | 7.4K |
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | New England Journal of Medicine | 2000 | 6.9K |
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Lancet, The | 2002 | 6.6K |
| Inflammation in atherosclerosis | Nature | 2002 | 6.5K |
| Inflammation, atherosclerosis, and coronary artery disease | New England Journal of Medicine | 2005 | 6.3K |
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | New England Journal of Medicine | 1995 | 6.2K |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | New England Journal of Medicine | 2011 | 6.2K |
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) | Lancet, The | 1998 | 6.1K |
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | New England Journal of Medicine | 1996 | 6K |
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | New England Journal of Medicine | 2015 | 5.9K |
| Apixaban versus warfarin in patients with atrial fibrillation | New England Journal of Medicine | 2011 | 5.8K |
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | BMJ: British Medical Journal | 2000 | 5.7K |
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | New England Journal of Medicine | 2001 | 5.4K |
| 10-year follow-up of intensive glucose control in type 2 diabetes | New England Journal of Medicine | 2008 | 5.2K |
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | New England Journal of Medicine | 1998 | 5.1K |
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Lancet, The | 1996 | 5.1K |
| Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction | New England Journal of Medicine | 2002 | 5.1K |
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | New England Journal of Medicine | 2001 | 5K |
| Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure | New England Journal of Medicine | 2005 | 4.9K |
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | New England Journal of Medicine | 2007 | 4.8K |
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | New England Journal of Medicine | 1992 | 4.7K |
